Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity.

RAD51 is a key protein in the homologous recombination (HR) pathway of DNA double-strand break repair, and HR represents a novel target for cancer therapy. Because imatinib (Gleevec) has been reported to reduce RAD51 protein levels, we tested the clonogenic survival for RT112, H1299, PANC1, and PC3...

全面介绍

书目详细资料
Main Authors: Choudhury, A, Zhao, H, Jalali, F, Al Rashid, S, Ran, J, Supiot, S, Kiltie, A, Bristow, R
格式: Journal article
语言:English
出版: 2009